Milestone Pharmaceuticals Shares Q3 2025 Earnings Insights

Author: Addison Perry Updated: 11-12-2025 07:14 AM

Milestone Pharmaceuticals Reports Financial Results

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) recently shared its financial results for the third quarter of 2025. The company is poised for significant developments as it approaches its PDUFA target date for CARDAMYST™ (etripamil) nasal spray.

Optimism Surrounding CARDAMYST Launch

With the Prescription Drug User Fee Act (PDUFA) target date set for December 13, 2025, there is a palpable sense of excitement around the potential approval of CARDAMYST for paroxysmal supraventricular tachycardia (PSVT). Joseph Oliveto, President and CEO of Milestone Pharmaceuticals, expressed optimism regarding the upcoming launch, emphasizing the importance of rapid market readiness.

Equity Financing Strengthens Financial Position

On September 30, 2025, the company reported a solid cash position of $82.6 million, bolstered by a successful equity offering earlier this year. The infusion of funds is expected to facilitate a swift and efficient launch of CARDAMYST following FDA approval.

Third Quarter Performance Highlights

Milestone continues to prepare extensively for the launch of its flagship product, CARDAMYST. The company's latest financial reporting reveals several key performance indicators for Q3 2025:

As of September 30, 2025, Milestone recorded no revenue for the third quarter or the same period the previous year.
Research and development expenses reached $3.9 million, slightly lower than the $4 million reported in the previous year.
General and administrative expenses totaled $3.3 million for Q3, down from $3.7 million last year.
Commercial expenses increased significantly to $4.6 million, reflecting heightened operational preparations for the product launch.
The company's net loss for the third quarter was reported at $11.9 million, compared to $9.4 million for the prior year.

Regulatory Updates and Launch Preparations

Milestone is not only focusing on PSVT but also on the potential of etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR). The company is gearing up to enter a pivotal Phase 3 program in AFib-RVR, taking lessons learned from the successful ReVeRA Phase 2 trial.

Investment Plans and Shareholder Value

Milestone's strategic focus includes leveraging its financial strength from the equity offering and amended royalty purchase agreement to support the development and commercialization of CARDAMYST. The company aims to create substantial shareholder value through its innovative cardiovascular treatment solutions.

Looking Ahead

With expectations of FDA approval for CARDAMYST on the horizon, Milestone Pharmaceuticals is optimistic about the first step towards bringing a new therapeutic option to patients managing symptomatic PSVT. Leadership remains committed to efficiently navigating the regulatory landscape while preparing for market entry. Investors are advised to keep a close watch on upcoming milestones as the company approaches its PDUFA date.

Frequently Asked Questions

What is CARDAMYST?

CARDAMYST is an investigational nasal spray containing etripamil, designed to treat symptomatic PSVT.

When is the PDUFA date for CARDAMYST?

The PDUFA date for CARDAMYST is set for December 13, 2025.

What were Milestone’s financials for Q3 2025?

Milestone reported a net loss of $11.9 million and no revenue in Q3 2025.

What are the company's plans for etripamil in AFib-RVR?

Milestone is preparing to enter a pivotal Phase 3 trial for etripamil in AFib-RVR, leveraging findings from previous studies.

How is Milestone funded for the launch of CARDAMYST?

The company is well-funded following a successful equity offering and an amended royalty purchase agreement, enhancing its capacity for a swift launch upon FDA approval.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.